Adaptimmune stock plunges after announcing Nasdaq delisting plans
Liquidia Corp NASDAQ:LQDA Chief Financial Officer Michael Kaseta sold 11,630 shares of common stock on October 13 at a price of $23.41, totaling approximately $272,258. The transaction comes as the $2.01 billion market cap company has delivered an impressive 100% return over the past year, with analysts maintaining a Strong Buy consensus. InvestingPro analysis reveals 12 additional key insights about LQDA’s performance and outlook.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a Rule 10b5-1 trading plan adopted on December 15, 2023. The shares were sold to cover taxes associated with the settlement of restricted stock units (RSUs) and performance stock units (PSUs) granted on January 11, 2023, January 11, 2024, and January 15, 2024. The company maintains a healthy financial position with a current ratio of 2.49, indicating strong liquidity to meet short-term obligations.
On October 10, Kaseta also exercised options to acquire 5,828 shares of common stock through the conversion of performance stock units.
Following these transactions, Kaseta directly owns 352,646 shares of Liquidia Corp. The reported holdings include unvested restricted stock units and shares acquired through the company’s employee stock purchase plan.
In other recent news, Liquidia Technologies reported its second-quarter earnings for 2025, showcasing a remarkable revenue performance. The company achieved $8.8 million in revenue, significantly exceeding the projected $3.92 million, primarily due to robust sales of its Yutrepia product. Despite a larger-than-expected loss per share of $0.49 against a forecasted $0.42, the earnings report was well-received. Following the earnings report, several analyst firms adjusted their price targets for Liquidia. BTIG raised its price target to $49 from $40, citing stronger-than-expected patient adoption with over 900 unique prescriptions. Raymond James also increased its target to $41 from $33, maintaining a Strong Buy rating due to positive metrics supporting Yutrepia’s launch. Wells Fargo adjusted its price target to $31 from $25, highlighting the strong launch performance with 94 unique patient prescriptions per week. Additionally, Jefferies initiated coverage with a Buy rating and a $43 price target, following the FDA approval of Yutrepia for pulmonary conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.